加载中
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
前收盘价
US$5.03
−US$0.12 · -2.33%
盘前
US$4.90
−US$0.13 · -2.58%
10月13日 5:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日内区间
当前US$5.03
52周区间
当前US$5.03
盘中时间采用ET。市场数据可能有所延迟。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日内区间
当前US$5.03
52周区间
当前US$5.03
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 3.51亿 USD |
| 销货成本 | — | 8336.7万 USD | 7009万 USD | 6239万 USD | 1.67亿 USD |
| 毛利 | — | −8336.7万 USD | −7009万 USD | −6239万 USD | 1.84亿 USD |
| 研究与开发 | 1.48亿 USD | 1.45亿 USD | 1.33亿 USD | 8883.6万 USD | 1.67亿 USD |
| 销售、一般及管理费用 | 3286.3万 USD | 4884.9万 USD | 4991.9万 USD | 4871.4万 USD | 4578.5万 USD |
| 营业费用 | 1.81亿 USD | 1.1亿 USD | 9407.2万 USD | 6826万 USD | 4578.5万 USD |
| 利息收入 | 1637.6万 USD | 2549万 USD | 2922.4万 USD | 1115.1万 USD | 21.3万 USD |
| 利息支出 | — | — | — | 1115.1万 USD | — |
| 折旧和摊销 | 41.6万 USD | 41.6万 USD | 41.6万 USD | 26万 USD | 2.9万 USD |
| 营业利润 | −1.81亿 USD | −1.93亿 USD | −1.64亿 USD | −1.31亿 USD | 1.38亿 USD |
| 净利润 | −1.58亿 USD | −1.68亿 USD | −1.36亿 USD | −1.16亿 USD | 1.21亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.00
上涨空间 39.17%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1087.26万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM958.06万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF457.86万0.00%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS316.16万0.01%338.04亿 USD0.31%US$78.17-0.23%
iShares Biotechnology ETFIBB258.7万0.02%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO217.94万0.01%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA187.27万0.01%217.13亿 USD0.03%US$32.66-0.40%
U.S. Micro Cap Portfolio ETFDFMC120.93万0.02%75.44亿 USD0.43%US$57.70-0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAU.S. Micro Cap Portfolio ETFDFMCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
